Publicacións en colaboración con investigadores/as de Complejo Asistencial de Segovia (21)

2023

  1. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

    Viruses, Vol. 15, Núm. 2

  2. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

    Viruses, Vol. 15, Núm. 4

2022

  1. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 342-349

2021

  1. Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 Registry

    PLoS ONE, Vol. 16, Núm. 2 February

2020

  1. Neuromuscular blockade management and postoperative outcomes in enhanced recovery colorectal surgery: Secondary analysis of POWER trial

    Minerva Anestesiologica, Vol. 87, Núm. 1, pp. 13-25

2019

  1. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64

  2. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort

    Liver International, Vol. 39, Núm. 1, pp. 90-97

2018

  1. Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain

    Diabetic Medicine, Vol. 35, Núm. 11, pp. 1605-1612

2017

  1. A protective personal factor against disability and dependence in the elderly: an ordinal regression analysis with nine geographically-defined samples from Spain

    BMC Geriatrics, Vol. 17, Núm. 1, pp. 1-10

  2. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  3. Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme

    PLoS ONE, Vol. 12, Núm. 3

  4. Response to bile salts in clinical strains of Acinetobacter baumannii lacking the adeABC efflux pump: Virulence associated with quorum sensing

    Frontiers in Cellular and Infection Microbiology, Vol. 7, Núm. MAY

  5. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822

2014

  1. Epidemiologic and clinical impact of acinetobacter baumannii colonization and infection: A reappraisal

    Medicine (United States), Vol. 93, Núm. 5, pp. 202-210

2011

  1. Medical, environmental and personal factors of disability in the elderly in Spain: A screening survey based on the International Classification of Functioning

    Gaceta Sanitaria, Vol. 25, Núm. SUPPL. 2, pp. 29-38

  2. Prevalence and European comparison of dementia in a ≥75-year-old composite population in Spain

    Acta Neurologica Scandinavica, Vol. 123, Núm. 5, pp. 316-324

  3. Prevalence of disability in a composite ≥75 year-old population in Spain: A screening survey based on the International Classification of Functioning

    BMC Public Health, Vol. 11

2009

  1. End-stage heart disease in the elderly

    Revista Espanola de Cardiologia, Vol. 62, Núm. 4, pp. 409-421

  2. Prevalence of dementia and major dementia subtypes in Spanish populations: A reanalysis of dementia prevalence surveys, 1990-2008

    BMC Neurology, Vol. 9, pp. 55

2007

  1. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: Second National Study (2003)

    Revista Espanola de Quimioterapia, Vol. 20, Núm. 2, pp. 222-229